Glycoconjugated Metallohelices have Improved Nuclear Delivery and Suppress Tumour Growth In Vivo

Hualong Song, Simon J. Allison, Viktor Brabec*, Hannah E. Bridgewater, Jana Kasparkova, Hana Kostrhunova, Vojtech Novohradsky, Roger M. Phillips*, Jitka Pracharova, Nicola J. Rogers*, Samantha L. Shepherd, Peter Scott*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

16 Citations (Scopus)

Abstract

Monosaccharides are added to the hydrophilic face of a self-assembled asymmetric FeII metallohelix, using CuAAC chemistry. The sixteen resulting architectures are water-stable and optically pure, and exhibit improved antiproliferative selectivity against colon cancer cells (HCT116 p53+/+) with respect to the non-cancerous ARPE-19 cell line. While the most selective compound is a glucose-appended enantiomer, its cellular entry is not mainly glucose transporter-mediated. Glucose conjugation nevertheless increases nuclear delivery ca 2.5-fold, and a non-destructive interaction with DNA is indicated. Addition of the glucose units affects the binding orientation of the metallohelix to naked DNA, but does not substantially alter the overall affinity. In a mouse model, the glucose conjugated compound was far better tolerated, and tumour growth delays for the parent compound (2.6 d) were improved to 4.3 d; performance as good as cisplatin but with the advantage of no weight loss in the subjects.

Original languageEnglish
Pages (from-to)14677-14685
Number of pages9
JournalAngewandte Chemie - International Edition
Volume59
Issue number34
DOIs
Publication statusPublished - 17 Aug 2020

User-Defined Keywords

  • antitumor agents
  • glycoconjugates
  • metallohelices
  • nuclear delivery
  • self-assembly

Fingerprint

Dive into the research topics of 'Glycoconjugated Metallohelices have Improved Nuclear Delivery and Suppress Tumour Growth In Vivo'. Together they form a unique fingerprint.

Cite this